GSK Quadrivalent Flu Vaccine Aims For Superiority Claim Over Trivalent Product
Executive Summary
MedImmune’s quadrivalent FluMist already has been approved, but the superiority advantage in one strain could give GSK’s version a critical marketing edge.
You may also be interested in...
Four-Strain Flu Vaccine Gains Traction With Sanofi’s sBLA Filing
Sanofi’s application for a quadrivalent flu vaccine comes eight months after FDA approved MedImmune’s quadrivalent and seven months after GSK’s filing; companies expect to transition to the four-strain vaccine.
Four-Strain Flu Vaccine Gains Traction With Sanofi’s sBLA Filing
CDC advisory committee to discuss the vaccines at its Oct. 25 meeting; Sanofi’s application for a quadrivalent flu vaccine comes eight months after FDA approved MedImmune’s quadrivalent and seven months after GSK’s filing.
Quadrivalent FluMist Clears FDA But Won’t Be On The Market Until 2013
MedImmune does not expect improved sales of the intranasal vaccine based on the enhanced formulation.